Prevalence and Determinants of Cervical Cancer Screening with a Combination of Cytology and Human Papillomavirus Testing

Overview

Journal Ann Epidemiol

Publisher Elsevier

Specialty Public Health

Date 2019 Jul 20

PMID 31320153

Citations 3

Authors

Joel Fokom Domgue

Sonia A Cunningham

Robert K Yu

Sanjay Shete

Affiliations

Soon will be listed here.

Abstract

Purpose: In the United States, recommended options for cervical cancer screening in women aged 30 years or older include cytology alone or a combination of cytology and human papillomavirus (HPV) testing (co-testing). Although there is a body of evidence suggesting that co-testing may be the preferred screening option in this group of women, little is known about the characteristics of women who screen for cervical cancer with co-testing.

Methods: A multistage area probability design-based survey was administered to a representative sample of Texas residents. Of the 1348 female respondents, 572 women aged 30 years or older were included in this analysis. Population-weighted survey logistic regression was used to identify determinants of cervical screening with co-testing versus screening with cytology alone.

Results: Women vaccinated against HPV (aOR: 4.48, 95% CI: 1.25-15.97) or hepatitis B virus [aOR: 2.48 (1.52-4.02)], those with a personal cancer history [aOR: 2.96 (1.29-6.77)], and hormonal contraception users [aOR: 2.03 (1.03-3.97)] were more likely to be screened with co-testing than with cytology alone. Moreover, the likelihood of being screened with co-testing decreased with increasing age and decreasing annual household income.

Conclusions: Benefits and indications of co-testing should be better explained to women and health care providers.

Citing Articles

Predictive value of hepatitis B serological indicators for mortality among cancer survivors and validation in a gastric cancer cohort.

Zhang Y, Qu L, Pan Y, Wu Y, Jiang J PLoS One. 2023; 18(12):e0286441.

PMID: 38150459 PMC: 10752528. DOI: 10.1371/journal.pone.0286441.

Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications.

Sausen D, Shechter O, Gallo E, Dahari H, Borenstein R Cancers (Basel). 2023; 15(14).

PMID: 37509353 PMC: 10378257. DOI: 10.3390/cancers15143692.

Prognostic impact of hepatitis B virus infection in patients with primary cervical cancer.

Feng X, Lu H, Wei Y, Guan M, Wang J, Liu C Cancer Med. 2021; 10(23):8310-8319.

PMID: 34672431 PMC: 8633261. DOI: 10.1002/cam4.4358.

References

Berwick D . A user's manual for the IOM's 'Quality Chasm' report. Health Aff (Millwood). 2002; 21(3):80-90. DOI: 10.1377/hlthaff.21.3.80. View

Scholefield J, Hickson W, Smith J, Rogers K, Sharp F . Anal intraepithelial neoplasia: part of a multifocal disease process. Lancet. 1992; 340(8830):1271-3. DOI: 10.1016/0140-6736(92)92961-e. View

Sheridan S, Harris R, Woolf S . Shared decision making about screening and chemoprevention. a suggested approach from the U.S. Preventive Services Task Force. Am J Prev Med. 2004; 26(1):56-66. DOI: 10.1016/j.amepre.2003.09.011. View

Mast E, Weinbaum C, Fiore A, Alter M, Bell B, Finelli L . A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006; 55(RR-16):1-33. View

Markowitz L, Dunne E, Saraiya M, Lawson H, Chesson H, Unger E . Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-2):1-24. View

Niederdeppe J, Gurmankin Levy A . Fatalistic beliefs about cancer prevention and three prevention behaviors. Cancer Epidemiol Biomarkers Prev. 2007; 16(5):998-1003. DOI: 10.1158/1055-9965.EPI-06-0608. View

Kulasingam S, Pagliusi S, Myers E . Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. Vaccine. 2007; 25(48):8110-3. DOI: 10.1016/j.vaccine.2007.09.035. View

Rauscher G, Johnson T, Cho Y, Walk J . Accuracy of self-reported cancer-screening histories: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008; 17(4):748-57. DOI: 10.1158/1055-9965.EPI-07-2629. View

Mathur M, Mathur V, Reichling D . Participation in the decision to become vaccinated against human papillomavirus by California high school girls and the predictors of vaccine status. J Pediatr Health Care. 2010; 24(1):14-24. DOI: 10.1016/j.pedhc.2008.11.004. View

10.

Goodman M, Shvetsov Y, McDuffie K, Wilkens L, Zhu X, Thompson P . Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the Hawaii HPV Cohort Study. J Infect Dis. 2010; 201(9):1331-9. PMC: 2851490. DOI: 10.1086/651620. View

11.

Espinosa de Los Monteros K, Gallo L . The relevance of fatalism in the study of Latinas' cancer screening behavior: a systematic review of the literature. Int J Behav Med. 2010; 18(4):310-8. PMC: 3212691. DOI: 10.1007/s12529-010-9119-4. View

12.

Katki H, Kinney W, Fetterman B, Lorey T, Poitras N, Cheung L . Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011; 12(7):663-72. PMC: 3272857. DOI: 10.1016/S1470-2045(11)70145-0. View

13.

Saslow D, Solomon D, Lawson H, Killackey M, Kulasingam S, Cain J . American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis. 2012; 16(3):175-204. PMC: 3915715. DOI: 10.1097/LGT.0b013e31824ca9d5. View

14.

Moyer V . Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 156(12):880-91, W312. DOI: 10.7326/0003-4819-156-12-201206190-00424. View

15.

Schumacher J, Witt W, Palta M, Loconte N, Heidrich S, Trentham-Dietz A . Cancer screening of long-term cancer survivors. J Am Board Fam Med. 2012; 25(4):460-9. PMC: 3506256. DOI: 10.3122/jabfm.2012.04.110118. View

16.

. ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol. 2012; 120(5):1222-38. DOI: 10.1097/aog.0b013e318277c92a. View

17.

Katki H, Schiffman M, Castle P, Fetterman B, Poitras N, Lorey T . Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis. 2013; 17(5 Suppl 1):S28-35. PMC: 3616419. DOI: 10.1097/LGT.0b013e318285423c. View

18.

Shepperd J, Howell J, Logan H . A survey of barriers to screening for oral cancer among rural Black Americans. Psychooncology. 2013; 23(3):276-82. PMC: 3943566. DOI: 10.1002/pon.3415. View

19.

Limmer K, LoBiondo-Wood G, Dains J . Predictors of cervical cancer screening adherence in the United States: a systematic review. J Adv Pract Oncol. 2014; 5(1):31-41. PMC: 4093462. View

20.

Fox J, Shaw F . Relationship of income and health care coverage to receipt of recommended clinical preventive services by adults - United States, 2011-2012. MMWR Morb Mortal Wkly Rep. 2014; 63(31):666-70. PMC: 4584657. View